Article Text

Download PDFPDF

Subject index

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

4T1 mammary carcinoma A21, P02.05

Activated B cells A29, P03.16

activation induced cell death A6, O6

acute myeloid leukaemia A13, P01.10

Acute Myeloid Leukemia A2, A32, A56, L4, P03.24, P09.09

acute myeloid leukemia, exosomes, DC A13, P01.11

adeno-associated virus (AAV) A47, P06.13

adenosine axis A22, P03.02

Adipose derived stem cells A25, P03.08

Adoptive cell therapy A44, A45, A58, P06.06, P06.10, P09.13

Adoptive T cell therapy A2, A41, L4, P06.01

Age A27, P03.13

allogeneic immune response A17, P01.18

AML A38, A58, P04.04, P09.12

anti-leukaemic functionality A13, P01.10

anti-PD1 A37, P04.03

Anti-tumor immunity A21, P02.03

anti-tumor immunotherapy A1, L1

Antibody A32, P03.25

anticancer vaccine A40, P04.09

Antigen processing- and presentation A53, P09.03

antisense oligonucleotide A22, P03.02

Arginase-1 A38, P04.05

B cell A40, P05.01

BCG A26, P03.09

Biochemical regulation A16, P01.17

Bioinformatics tools A30, P03.21

Biomarkers A46, P06.11

bispecific antibodies A11, A41, P01.07, P06.01

Bispecific T cell engagers A2, L4

Bispecific VHH A6, O7

Bladder cancer A26, P03.09

breast cancer A8, A29, A44, A50, A52, P01.02, P03.17, P06.08, P08.03, P09.02

Cancer A39, P04.08

Cancer stem cells A36, P04.01

Cancer Testis Antigens A49, P07.02

canine scent detection A9, P01.03

CAR A45, P06.09

CAR T cell therapy A20, A42, P02.01, P06.02

CAR T cells A6, A42, A43, A44, A55, O6, P06.03, P06.05, P06.07, P09.08

CAR-NK cell therapy A46, A47, P06.12, P06.13

CAR-T A48, P06.15

CART A54, P09.05

CCL22 A55, P09.07

CD112R A22, P03.01

CD19 CAR T cells A48, P07.01

CD39 A47, P06.14

CD47 A58, P09.12

CD8+ cytotoxic T cells A24, P03.06

cellular reporter system A19, P01.23

cFLIP A6, O6

Checkpoint blockade A27, P03.13

Checkpoint inhibitors A45, A46, A49, P06.10, P06.12, P08.01

Chemo-Immunotherapy A7, O8

Chemokine receptors A42, P06.03

chemokines A15, A26, P01.14, P03.11

chemoresistance A33, P03.27

Chemotherapy A18, P01.21

Chimeric Antigen Receptors A46, P06.11

CML A54, P09.06

colorectal cancer A27, P03.12

combination therapy A35, P03.31

combinatorial treatment A34, P03.29

complementary substances A14, P01.12

CRISPR/Cas A54, P09.06

Cutaneous T cell lymphoma A4, O3

CXCR6 A44, P06.07

Cytokine-Induced Killer cells A44, A51, A58, P06.06, P09.01, P09.13

cytotoxic T cells A3, O1

cytotoxicity A4, O2

DC vaccination A38, P04.04

Deep Spatial Profiling A24, P03.05

Dendritic cells A5, A35, A36, A39, A40, O5, P03.31, P04.01, P04.06, P04.09

DGK-α A11, P01.08

Diffuse large B cell lymphomas A1, L2

DLBCL A48, P07.01

drug synergy A59, P09.14

dual signalling protein A12, P01.09

ectonucleotidases A22, P03.02

electronic Nose A9, P01.03

Endogenous Retrovirus A39, P04.08

Exercise oncology A41, P05.02

Exhaustion A19, P01.24

Extracellular HSPs A32, P03.25

Follicular lymphoma A53, P09.03

GL261 A29, P03.19

glioblastoma A46, A47, P06.12, P06.13

Glioma A57, P09.10

Gvax A31, P03.23

head and neck cancer A33, P03.26

Head and Neck Squamous Cell Carcinoma A46, P06.11

hematological malignancies A51, P09.01

HLA class II presentation A20, P02.02

HPV status A33, P03.26

human anti-murine antibody A54, P09.05

Human CD22 A30, P03.20

Hyperthermia A49, P08.01

Hypoxia A29, A33, P03.16, P03.27

iCAR A19, P01.23

IDO A37, P04.03

IDO1 A43, P06.05

IFN-gamma signature A15, P01.15

immune cell stimulation A14, P01.12

Immune checkpoint blockade A5, O4

immune checkpoint inhibitors A21, P02.05

immune checkpoint targeting A12, P01.09

immune checkpoints A11, A28, P01.08, P03.15

Immune escape A16, P01.17

Immune evasion A17, A28, P01.20, P03.15

immune landscape evolution A31, P03.23

immune microenvironment A53, P09.03

Immune modulatory vaccine A37, P04.03

immune response A40, P05.01

immune therapy A14, P01.12

Immunofluorescence A25, P03.07

Immunogenic Cell Death A21, A32, P02.03, P03.24

immunogenicity A29, A54, P03.19, P09.05

Immunology A34, A59, P03.28, P09.15

immunomodulatory markers A44, P06.08

immunophenotype A27, P03.12

Immunosuppression A21, A22, P02.04, P02.06

immunotherapy A2, A3, A6, A15, A21, A22, A26, A28, A31, A48, A50, A50, A57, L3, L5, O7, P01.15, P02.03, P02.06, P03.09, P03.15, P03.22, P06.15, P08.02, P08.03, P09.10

Immunotherapy prediction A4, O3

Immunotherapy vaccine A36, P04.01

immunotoxin A59, P09.14

In silico modeling A41, P05.02

inducible expression control A18, P01.22

inhibitory immunoreceptor A19, P01.23

innate/adaptive immune system A12, P01.09

Interleukin 2 A49, A53, P08.01, P09.04

intra-vital microscopy A1, L2

ipilimumab A51, P08.04

ITF3756 A19, P01.24

lactic acidosis A3, O1

leukaemia derived DC A13, P01.10

leukemia A33, P03.27

leukemic stem cells A58, P09.12

liposomes A50, P08.02

live cell imaging A3, O1

LLC1 A29, P03.19

Local therapy A57, P09.10

lung cancer A9, P01.03

Lymph nodes A34, P03.28

Lymph-node resident dendritic cells A52, P09.02

Lymphatic vessels A25, P03.08

Lymphoma A20, P02.01

Lymphoma mouse model A30, P03.20

macrophages A31, P03.22

MDSCs A38, P04.05

melanoma A3, A39, A41, L5, P04.06, P06.01

melanoma-in-skin model A5, O5

Memory A19, P01.24

MERTK A14, P01.13

mesothelin A11, P01.07

Metaflammation A17, P01.18

metastasis A27, P03.12

Microbiome A20, P02.01

microbiome and immune system A57, P09.11

microenvironment A35, P03.31

Microfluidics A25, P03.07

microRNA A43, P06.04

Mitochondria fusion A42, P06.02

monoclonal antibodies A51, P09.01

MSI Colorectal Tumors A24, P03.05

MSS Colorectal Tumors A24, P03.05

Mucormycosis A56, P09.09

Multiple myeloma A49, P07.02

multiplex imaging A9, A10, A10, P01.04, P01.05, P01.06

Multiplexed tissue imaging A47, P06.14

Multiplexing A23, A25, P03.04, P03.07

myeloid leukocytes A15, P01.14

Myeloid-derived suppressor cells A26, P03.11

neo-antigens A20, P02.02

neoadjuvant A2, A15, L3, P01.15

neoadjuvant chemoradiotherapy A51, P08.04

neoadjuvant chemotherapy A44, P06.08

neoantigen load A8, P01.02

neoantigens A35, A38, P03.30, P04.04

neutrophils A15, A29, P01.14, P03.17

nivolumab A51, P08.04

NK cells cytotoxicity A32, P03.24

nk-92 A45, P06.09

non-viral gene transfer A55, P09.08

NOX2 A21, P02.04

NSCLC A34, P03.28

Obesity A17, P01.18

oncolytic viruses A40, A53, P04.09, P09.04

Ovarian cancer A45, P06.10

Ovarian carcinoma A25, P03.08

overall survival A8, P01.02

pancreatic cancer A7, A43, A59, O8, P06.05, P09.15

pancreatic ductal adenocarcinoma A23, A34, P03.03, P03.29

Patient-derived head and neck cancer A27, P03.14

PD-1 checkpoint blockade A56, P09.09

personalized immuno-oncology research A27, P03.14

phagocytosis A50, P08.02

phenotyping A23, P03.04

Philadelphia chromosome A54, P09.06

Precision medicine A41, P05.02

prostate cancer A45, P06.09

RANKL A50, P08.03

real-world data A48, P07.01

Regulatory FoxP3+ lymphocytes A26, P03.10

regulatory t-cell A53, P09.04

repertoire A40, P05.01

RIG-I A3, L5

rMVA-CD40L A37, P04.02

RNAi A11, P01.08

Romo1 inhibitors A18, P01.21

ROR-1 A55, P09.08

ROS A18, P01.21

Secondary lymphoid organs A23, P03.03

senescent cells A16, P01.16

sentinel lymph nodes A52, P09.02

Serum free A58, P09.13

Single-Cell A4, A48, O2, P06.15

single-cell RNA-seq A30, P03.21

solid tumors A11, A42, A43, A44, P01.07, P06.03, P06.04, P06.07

spatial distribution A23, P03.04

stage III melanoma A2, L3

STAT3 proteins A16, P01.16

STING Agonist A7, P01.01

Surgery-induced inflammation A22, P02.06

T cell bispecific antibody A1, L2

T cell differentiation A35, P03.30

T cell persistent A42, P06.02

T cell trafficking A5, O4

T cells A4, A14, A22, A43, O2, P01.13, P03.01, P06.04

TAM receptors A14, P01.13

TCR gene therapy A49, P07.02

technology A9, A10, A10, P01.04, P01.05, P01.06

tertiary lymphoid structures A23, P03.03

TGF-beta A1, L1

Tim-3-galectin-9 pathway A16, A17, P01.17, P01.20

TME A32, P03.25

Toll-like receptors A57, P09.11

translational research A57, P09.11

Treg depletion A31, P03.23

Triple Negative Breast Cancer cells A44, P06.06

tumor A31, P03.22

Tumor associated macrophages A38, P04.05

tumor immune suppression A5, O5

Tumor infiltrating lymphocytes A24, A26, A33, P03.06, P03.10, P03.26

Tumor microenvironment A4, A9, A10, A10, A22, A24, A26, A30, A59, O3, P01.04, P01.05, P01.06, P03.01, P03.06, P03.10, P03.20, P09.15

tumor targeting antibodies A37, P04.02

tumor-infiltrating lymphocytes A34, P03.29

Tumor-infiltrating T cells A30, A47, P03.21, P06.14

Tumour angiogenesis A5, O4

type I Interferon A1, L1

unfolded protein response A59, P09.14

uPA-PAI-1 A29, P03.17

Vγ9Vδ2 T cells A6, O7

Vaccine A39, A39, P04.06, P04.08

Vaccine therapy A55, P09.07

Von Hippel Lindau A29, P03.16

xenogeneic antibody A21, P02.05